Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): A Children's Oncology Group Report

2005 ◽  
Vol 46 (2) ◽  
pp. 193-197 ◽  
Author(s):  
Anne L. Angiolillo ◽  
J. Whitlock ◽  
Z. Chen ◽  
M. Krailo ◽  
G. Reaman
2009 ◽  
Vol 53 (6) ◽  
pp. 978-983 ◽  
Author(s):  
Anne L. Angiolillo ◽  
Alice L. Yu ◽  
Gregory Reaman ◽  
Ashish M. Ingle ◽  
Rita Secola ◽  
...  

2021 ◽  
pp. 106749
Author(s):  
Jane L. Liesveld ◽  
Andrea Baran ◽  
Mitra Azadniv ◽  
Haley Misch ◽  
Katherine Nedrow ◽  
...  

2013 ◽  
Vol 3 (5) ◽  
pp. 345-350
Author(s):  
S Shrestha ◽  
J Shrestha ◽  
CB Pun ◽  
T Pathak ◽  
S Bastola ◽  
...  

Background: Immunophenotyping of acute leukemia is one of the most important clinical applications of fl ow cytometry. The aim of this study was to determine the immunophenotyping profi le of acute leukemia, by means of a fl ow cytometric method, using monoclonal antibodies all marked with a fl uorochrome, in four colour systems to assess their distribution according to type of leukemia (lymphoid B or T / myeloid). Materials and Methods: We retrospectively collected data of immunophenotyping from 52 acute leukemia patients at the department of pathology in B.P. Koirala Memorial Cancer Hospital from January 2010 to December 2011. Diagnosis was based on peripheral blood and bone marrow examination for morphology, cytochemistry and immunophenotypic studies. Results: Out of total 52 cases of acute leukemia diagnosed by fl ow cytometry over a two year period, there were 31 cases (59.6 %) of acute lymphoblastic leukemia, 20 cases (38.4 %) of acute myelogenous leukemia and one case (1.9 %) of bi-phenotypic acute leukemia. Leukemia was diagnosed among adults in 44.2 % whereas among children with age less than or equal to 15 years in 55.7 %. Thirty eight (73%) were male and 14 (27 %) were female with a male: female ratio of 2.7:1. For acute myelogenous leukemia, it was found that M0 (5.0 %), M1 (20%), M2 (60%), M3 (15%), M4 (5.0 %) were detected. CD13 and CD33 were the most useful markers in the diagnosis of acute myelogenous leukemia. The most common subtype was AML-M2. Of the 31 cases with acute lymphoblastic leukemia, 20 cases (64.5 %) were identifi ed as B-ALL and 11 cases (35.5%) as T-ALL. Aside from cytoplasmic CD3 (cCD3) and CD7 were the most sensitive antigens present in all cases of T-ALL. All cases of B-ALL showed expression of pan B-cell markers CD19 and CD22, but 15 (75 %) of 20 cases expressed CD10. Conclusion: Flow cytometric immunophenotyping was found to be especially useful in the correct identifi cation and diagnosis of acute myeloid or lymphoblastic leukemia and its subtypes. In combination with French-American-British (FAB) morphology and immunophenotyping, we were able to diagnose and classify all patients with acute leukemia in this study. Journal of Pathology of Nepal (2013) Vol. 3, No.1, Issue 5, 345-350 DOI: http://dx.doi.org/10.3126/jpn.v3i5.7856


2020 ◽  
Vol 20 (4) ◽  
pp. 226-233.e1
Author(s):  
Benjamin K. Tomlinson ◽  
Molly M. Gallogly ◽  
Donna M. Kane ◽  
Leland Metheny ◽  
Hillard M. Lazarus ◽  
...  

Cancer ◽  
1989 ◽  
Vol 63 (5) ◽  
pp. 813-817 ◽  
Author(s):  
Hagop M. Kantarjian ◽  
Michael J. Keating ◽  
Ronald S. Walters ◽  
Charles A. Koller ◽  
Kenneth B. McCredie ◽  
...  

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 7026-7026 ◽  
Author(s):  
G. J. Schiller ◽  
D. DeAngelo ◽  
N. Vey ◽  
S. Solomon ◽  
R. Stuart ◽  
...  

1998 ◽  
Vol 20 (4) ◽  
pp. 347-352 ◽  
Author(s):  
Hans-Christoph Rossbach ◽  
Maxine J. Sutcliffe ◽  
Wilfredo Chamizo ◽  
Mary M. Haag ◽  
Nanette H. Grana ◽  
...  

1990 ◽  
Vol 8 (11) ◽  
pp. 1907-1912 ◽  
Author(s):  
R Ohno ◽  
K Okada ◽  
T Masaoka ◽  
A Kuramoto ◽  
T Arima ◽  
...  

An early phase II study of a new camptothecin analog and an inhibitor of topoisomerase I, CPT-11, was conducted in 62 patients with refractory leukemia and lymphoma by four different treatment schedules in a multiinstitutional cooperative study. CPT-11 therapy resulted in four complete remissions (CRs) and three partial remissions (PRs) in 29 assessable non-Hodgkin's lymphoma (NHL) patients, one PR in three Hodgkin's disease (HD), one CR and one PR in 11 acute lymphoblastic leukemia (ALL), and one PR in 15 acute myelogenous leukemia (AML) patients. Single infusion of 200 mg/m2 every 3 to 4 weeks produced no response in both leukemia and lymphoma patients. Sixty-minute infusions of 40 mg/m2/d for 5 days every 3 to 4 weeks or for 3 days weekly produced four CRs (17%) and four PRs (17%) in 24 patients with malignant lymphoma. Sixty-minute infusions of 20 mg/m2 twice a day for 7 days every 3 to 4 weeks resulted in one CR and two PRs in 12 patients with acute leukemia. No response was seen in an acute leukemia patient by another treatment schedule. CPT-11 was effective in two (15%) of 13 primarily refractory leukemia and lymphoma cases, in two of four relapsed cases, and in seven (17%) of 41 relapsed and refractory cases. Major side effects were leukopenia (91%) and gastrointestinal (GI) (76%). CPT-11 was shown to be effective against refractory leukemia and lymphoma, and thus deserves further clinical study; the novel antitumor activity mode of this drug predicts no cross-resistance to presently available antitumor drugs.


2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 6541-6541 ◽  
Author(s):  
F. J. Giles ◽  
S. O’Brien ◽  
N. Vey ◽  
E. Feldman ◽  
D. Rizzieri ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document